Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PANGEA-Breast: Pembrolizumab + Gemcitabine in HER2-negative ABC
NCT03025880Phase 2Completed
- Sponsor
- GEICAM
- Start
- Jun 2017
- Primary completion
- Jun 2019
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of pembrolizumab in breast cancer, sponsored by GEICAM. Started Jun 2017; status: completed.
02
Drugs
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT03025880.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03025880.